Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03480750 · OUTCOME

Overall Survival

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer · Source last updated 2020-11-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
36 months

What was measured

Time is calculated from the diagnosis to the date of the last follow-up date if no death event, or the date of death.

Analysis population: According the protocol for this secondary outcome, data collected from participants receiving different dose levels were intended to be combined and analyzed as a single group

Groups in this outcome

Trientine With Chemotherapy

trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1 trientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels) pegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1 carboplatin: carboplatin AUC 4 IV D1

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Trientine With Chemotherapy16

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Trientine With Chemotherapy14.4Not reported034.2Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        34.2
        value
        14.4
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    units
    Participants
description
Time is calculated from the diagnosis to the date of the last follow-up date if no death event, or the date of death.
dispersion Type
95% Confidence Interval
groups
  1. description
    trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1 trientine dihydrochloride: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels) pegylated liposomal doxorubicin: pegylated liposomal doxorubicin 40mg/m2 IV D1 carboplatin: carboplatin AUC 4 IV D1
    id
    OG000
    title
    Trientine With Chemotherapy
param Type
MEDIAN
population Description
According the protocol for this secondary outcome, data collected from participants receiving different dose levels were intended to be combined and analyzed as a single group
reporting Status
POSTED
time Frame
36 months
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice